Incannex Healthcare Inc. 8K

Incannex Healthcare Inc. reported progress in its IHL-42X and PSX-001 clinical programs, a new long-dated U.S. patent for IHL-42X, and a solid cash position of about $70 million with no debt as of August 31, 2026.

Incannex Healthcare Inc. filed a Form 8-K to furnish a corporate update press release announcing the commencement of patient dosing in the DReAMzz Phase 2 dose-optimization study of its IHL-42X candidate for obstructive sleep apnea across 13 U.S. sites, the June 25, 2026 grant of a U.S. composition and methods-of-treatment patent for IHL-42X expiring in 2040, continued advancement of its PSX-001 oral synthetic psilocybin program for generalized anxiety disorder following positive Phase 2 data and ongoing U.S. and UK regulatory engagement, and confirmation of a strong capital position with approximately $70 million in cash and no debt as of August 31, 2026, supported by over A$11.2 million of non-dilutive Australian R&D tax incentive receipts during 2026.

Filing Facts

CIK

1873875

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-098213

Alert Tier

6